FDA approves Zytiga for late-stage prostate cancer

Posted by (author unknown) on Thursday Apr 28, 2011 Under Uncategorized

The U.S. Food and Drug Administration today approved Zytiga (abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).

Be Sociable, Share!

Comments are closed.